US Glucosamine Prices Hold Steady Through August Amid Balanced Market Conditions

Glucosamine FOB remained effectively flat from July through late August 2026, as balanced supply and demand kept the US spot market within a narrow trading range. Early July assessments showed steady availability for East Coast formulators, and this Glucosamine market pattern continued through late August without material weekly movement. Domestic finishers maintained normal operating schedules, while Glucosamine buyers compared local availability with imports amid elevated logistics costs. Overall, the market remained calm ahead of Q4 procurement, with stable Glucosamine quotations limiting directional momentum.

Demand for Glucosamine was primarily supported by the US dietary-supplement sector, where brands and retailers prepared joint-health and osteoarthritis-support products for holiday retail programs. Pet-nutrition and pharmaceutical/OTC applications provided additional steady Glucosamine offtake. East Coast contract manufacturers maintained formulation and repackaging activity, supporting finished-product throughput. Glucosamine supply concentration remained an important factor, with an estimated 70–80% of global raw supply originating from China. Section 301 tariffs of around 15–25% continued to raise landed import costs, while an  manufacturing reading of 55.6 and consumer inflation of 3.5% indicated a relatively constructive demand backdrop.

On the supply side, Glucosamine crustacean-shell raw-material availability remained adequate, allowing Asian exporters to maintain regular shipments. However, higher fuel, marine-insurance and freight expenses increased processing and export costs. Shanghai–New York freight rose by approximately 23.3%, adding to landed-cost pressure and providing a cost-push floor for US Glucosamine FOB assessments. Domestic producers reported normal operations without significant maintenance outages, limiting immediate production-side tightness. Nevertheless, renewed geopolitical disruption, higher energy costs or rising marine-insurance premiums could create upside risks.

Weekly Glucosamine pricing showed consistency rather than volatility from early July through late August. Steady supplement demand and sufficient supply offset the impact of higher freight and tariff costs, keeping the market sideways. Traders largely maintained existing purchasing strategies as routine contract-manufacturing activity and adequate inventories reduced the need for aggressive spot buying.

Looking ahead, the Glucosamine market is expected to remain flat to modestly firm into Q4 2026 and January 2027. Seasonal procurement for holiday production and potential Lunar New Year stockpiling could strengthen autumn and early-winter demand. A low-single-digit price uptick is possible toward January if replenishment accelerates. Meanwhile, tariff-related import costs and elevated freight should continue supporting US Glucosamine price levels. Any sharp feedstock, energy, shipping or geopolitical disruption could intensify cost-push pressure, keeping the outlook conditionally bullish.